This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antares Pharma Appoints Dr. Bruce Freundlich As Senior Vice President

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Bruce Freundlich to the position of Senior Vice President, Medical. Dr. Freundlich holds an MD from the Mount Sinai School of Medicine and an MBA from the University of Massachusetts, Amherst. He completed his rheumatology training at the University of Pennsylvania where he was subsequently a member of faculty. He is currently an adjunct professor of medicine at the University of Pennsylvania and a volunteer staff member of the Philadelphia Veterans Administration.

As the former Chief of Clinical Rheumatology at Penn, Dr. Freundlich performed the first trial in rheumatology with a recombinant protein, gamma interferon in scleroderma patients based upon prior laboratory research which he had published. He then went on into industry starting at Merck where he was a medical director of the Mid-Atlantic Region and then on to Wyeth/Pfizer where he became a multi-therapeutic Vice President of Immunology and Musculo-Skeletal Diseases. While at Wyeth, his team was the first to use remission as a primary endpoint in rheumatoid arthritis for a trial called COMET. Dr. Freundlich has authored over 100 original publications and abstracts which have been presented around the world and he has been a reviewer for the Annals of Internal Medicine, the Lancet, Arthritis and Rheumatism and multiple other journals.

“We are very pleased to welcome Dr. Freundlich to the Antares team,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “Bruce’s broad experience both in industry and academia as a practicing and highly regarded rheumatologist will be valuable as we commercialize OTREXUP . Dr Freundlich is well known to his peers through his numerous publications and active participation in professional association meetings including ACR and EULAR. Everyone associated with Antares is excited about his joining the organization at a time when we are establishing our own commercial presence in the rheumatology field.”

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company has received marketing approval from the U.S. Food and Drug Administration for OTREXUP™ (methotrexate) injection for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing VIBEX ® QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX ® disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet ® and Zomajet ® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin ® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX ® epinephrine and several other products. Antares Pharma’s partnership with Ferring includes Zomacton ® hGH (somatropin) injection. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin ® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company’s corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs